Posts by: Marta Figueiredo

News

Capricor Therapeutics’ vesicle-based therapy CAP-2003, derived from the company’s proprietary cardiosphere-derived cells (CDCs), may be an effective therapy for Duchenne muscular dystrophy (DMD), according to preclinical data. The company ... Read more

June 22, 2018February 25, 2019

Microdystrophin Gene Therapy Shows Promising Interim Results in Phase 1/2 Trial

News

Microdystrophin gene therapy robustly induces the production of a shorter, but functional, version of the dystrophin protein and reduces muscle damage in Duchenne muscular dystrophy (DMD) patients, according to ... Read more

February 12, 2018

New CRISPR Strategy Corrects Wider Range of Mutations Responsible for DMD

News

A new approach to CRISPR-Cas9 gene-editing technology, called myoediting, successfully restored dystrophin production and contraction force in heart muscle cells of Duchenne muscular dystrophy (DMD) patients. The new strategy, developed ... Read more

January 26, 2018

Ezutromid Reduces Muscle Damage in DMD Patients, Interim Data of Phase 2 Trial Shows

News

Ezutromid significantly reduced muscle damage in patients with Duchenne muscular dystrophy (DMD) after 24 weeks of treatment in a Phase 2 trial, Summit Therapeutics recently announced. DMD is a severe ... Read more

Posts by: Marta Figueiredo

Marta Figueiredo

Capricor’s Vesicle-based Therapy Holds Promise to Treat DMD, Preclinical Data Suggests

Microdystrophin Gene Therapy Shows Promising Interim Results in Phase 1/2 Trial

New CRISPR Strategy Corrects Wider Range of Mutations Responsible for DMD

Ezutromid Reduces Muscle Damage in DMD Patients, Interim Data of Phase 2 Trial Shows

Pin It on Pinterest